ClinicalTrials.gg
Active, not recruitingNCT04755283AZALEA-TIMI 71Updated Nov 6, 2025Results posted

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

A Phase 2 interventional study of Abelacimab and Rivaroxaban in Atrial Fibrillation (AF) and Stroke, sponsored by Anthos Therapeutics, Inc.. Active, not recruiting at 92 sites in 7 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Anthos Therapeutics, Inc. · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,287
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 993 studies in Atrial Fibrillation with a site in United States — 161 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
71st of 679
1,287 · median 127
Started
2021
with 57 others
Phase 2
55 of 993
7 open now
Primary completion
2024-02
later than 6 of 219 live
Registered
712th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 71st largest by enrollment of the 679 interventional ones that give a count, is one of 58 that started in 2021, is one of 55 in phase 2, reaches primary completion later than 6 of the 219 other live ones, and was the 712th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

161 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Stroke

Keywords

  • randomized
  • prospective
  • blinded endpoint evaluation
  • abelacimab
  • MAA868
  • rivaroxaban
  • atrial fibrillation
  • Factor XI
  • stroke
  • bleeding events
  • anti-coagulant
  • anticoagulation therapy
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥ 55 years old
  • Patients with a history of atrial fibrillation (AF) or atrial flutter with planned indefinite anticoagulation
  • Patients with a CHA2DS2-VASc of ≥4 OR a CHA2DS2-VASc of ≥3 with at least 1 of the following:

    1. Planned concomitant use of antiplatelet medication use (i.e., aspirin and/or P2Y12 inhibitor) for the duration of the trial
    2. (CrCl) ≤50 ml/min by the Cockcroft-Gault equation

Exclusion criteria

Exclusion Criteria:

  • History of to any of the study drugs (including rivaroxaban) or its , to drugs of similar chemical classes, or any listed in the label for rivaroxaban
  • Patients with an intracranial or intraocular bleed within the 3 months prior to screening
  • mitral stenosis (valve area \<1.5 cm2)
  • Mechanical heart valve or other indication for anticoagulation therapy other than atrial fibrillation (e.g., venous thromboembolism)
  • Known presence of an atrial myxoma or left ventricular thrombus
  • History of left atrial appendage closure or removal
  • Active endocarditis

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,287 participants (actual)

Study arms

  • Experimental
    Abelacimab 90 mg (MAA868)

    Treatment group 1: Abelacimab low dose subcutaneous (s.c.) monthly Extension Treatment Group: Abelacimab high dose subcutaneous (s.c.) monthly

    Biological: Abelacimab

  • Experimental
    Abelacimab 150 mg (MAA868)

    Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly Extension Treatment Group: Abelacimab high dose subcutaneous (s.c.) monthly

    Biological: Abelacimab

  • Active comparator
    Rivaroxaban

    Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily.

    Drug: Rivaroxaban

Interventions

  • BiologicalAbelacimab

    Abelacimab provided as liquid in vial (150 mg/mL)

    Also known as: MAA868

  • Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets

06

What researchers measure

Primary outcomes

  1. Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding Events

    The number of participants experiencing the first occurrence of the composite of ISTH-defined major bleeding or CRNM bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.

    Time frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.

Secondary outcomes

  1. Incidence Rate of the First Occurrence of ISTH-defined Major Bleeding Events

    The number of participants experiencing the first occurrence of ISTH-defined major bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.

    Time frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.

  2. Incidence Rate of the First Occurrence of ISTH-defined Major or CRNM or Minor Bleeding Events

    The number of participants experiencing the first occurrence of the composite of ISTH-defined major or CRNM or minor bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.

    Time frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.

07

Results

Posted Jul 30, 2025
Limitations and caveats
The independent data monitoring committee recommended early termination of the trial on September 14, 2023.

Participant flow

Participant flow — Overall Study
MilestoneAbelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)Rivaroxaban
Started427430430
Entered open-label250240215
Completed382391389
Not completed453941
Withdrew: Withdrawal by subject1436
Withdrew: Lost to follow-up001
Withdrew: Death313634

Outcome measures

PrimaryIncidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding Events

The number of participants experiencing the first occurrence of the composite of ISTH-defined major bleeding or CRNM bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.

Time frame:
Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
Reported as:
Number · participants with event/100 person-years
Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding Events
participants with event/100 person-yearsAbelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)Rivaroxaban
Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding Events2.643.228.39
Statistical analysis
  • Abelacimab 90 mg (MAA868) vs Rivaroxaban · Stratified Log Rank Test · p = <0.001 · Hazard ratio (hr): 0.314 · 95% CI 0.192 to 0.513Cox Proportional Hazards Model Adjusted for Stratification Factors
  • Abelacimab 150 mg (MAA868) vs Rivaroxaban · Stratified Log Rank Test · p = <0.001 · Hazard ratio (hr): 0.382 · 95% CI 0.243 to 0.602Cox Proportional Hazards Model Adjusted for Stratification Factors
SecondaryIncidence Rate of the First Occurrence of ISTH-defined Major Bleeding Events

The number of participants experiencing the first occurrence of ISTH-defined major bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.

Time frame:
Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
Reported as:
Number · participants with event/100 person-years
Incidence Rate of the First Occurrence of ISTH-defined Major Bleeding Events
participants with event/100 person-yearsAbelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)Rivaroxaban
Incidence Rate of the First Occurrence of ISTH-defined Major Bleeding Events0.991.223.73
Statistical analysis
  • Abelacimab 90 mg (MAA868) vs Rivaroxaban · Stratified Log Rank Test · p = <0.001 · Hazard ratio (hr): 0.263 · 95% CI 0.121 to 0.572Cox Proportional Hazards Model Adjusted for Stratification Factors
  • Abelacimab 150 mg (MAA868) vs Rivaroxaban · Stratified Log Rank Test · p = 0.001 · Hazard ratio (hr): 0.325 · 95% CI 0.159 to 0.663Cox Proportional Hazards Model Adjusted for Stratification Factors
SecondaryIncidence Rate of the First Occurrence of ISTH-defined Major or CRNM or Minor Bleeding Events

The number of participants experiencing the first occurrence of the composite of ISTH-defined major or CRNM or minor bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.

Time frame:
Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
Reported as:
Number · participants with event/100 person-years
Incidence Rate of the First Occurrence of ISTH-defined Major or CRNM or Minor Bleeding Events
participants with event/100 person-yearsAbelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)Rivaroxaban
Incidence Rate of the First Occurrence of ISTH-defined Major or CRNM or Minor Bleeding Events7.0510.4315.30
Statistical analysis
  • Abelacimab 90 mg (MAA868) vs Rivaroxaban · Stratified Log Rank Test · p = <0.001 · Hazard ratio (hr): 0.460 · 95% CI 0.332 to 0.638Cox Proportional Hazards Model Adjusted for Stratification Factors
  • Abelacimab 150 mg (MAA868) vs Rivaroxaban · Stratified Log Rank Test · p = 0.010 · Hazard ratio (hr): 0.683 · 95% CI 0.512 to 0.912Cox Proportional Hazards Model Adjusted for Stratification Factors

Adverse events

Collected over Adverse events (AEs) that started during or after the start of the treatment or started prior to the start of the treatment and increased in severity after the start of the treatment through each participant's derived End of Study date for the randomized period (up to 33 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abelacimab 90 mg (MAA868)31/427 (7.3%)158/425 (37.2%)215/425 (50.6%)
Abelacimab 150 mg (MAA868)36/430 (8.4%)157/427 (36.8%)257/427 (60.2%)
Rivaroxaban34/430 (7.9%)167/428 (39%)227/428 (53%)
Most frequent serious events
Showing 10 of 336
Most frequent serious events
EventAbelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)Rivaroxaban
Cardiac failureCardiac disorders26/42520/42718/428
Atrial fibrillationCardiac disorders18/42514/42710/428
PneumoniaInfections and infestations10/42510/42713/428
Gastrointestinal haemorrhageGastrointestinal disorders1/4253/42712/428
AnaemiaBlood and lymphatic system disorders1/4253/42711/428
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders10/4252/4276/428
COVID-19 pneumoniaInfections and infestations9/4251/4273/428
DeathGeneral disorders9/4254/4276/428
Acute respiratory failureRespiratory, thoracic and mediastinal disorders7/4253/4275/428
Urinary tract infectionInfections and infestations4/4257/4271/428
Most frequent other events
Most frequent other events
EventAbelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)Rivaroxaban
COVID-19Infections and infestations41/42548/42745/428
Atrial fibrillationCardiac disorders28/42527/42724/428
Urinary tract infectionInfections and infestations27/42524/42712/428
ContusionInjury, poisoning and procedural complications10/42527/42715/428
HeadacheNervous system disorders13/42527/42711/428
ArthralgiaMusculoskeletal and connective tissue disorders23/42526/42727/428
EpistaxisRespiratory, thoracic and mediastinal disorders11/4259/42727/428
HypertensionVascular disorders24/42526/42720/428
Back painMusculoskeletal and connective tissue disorders20/42526/42722/428
AnaemiaBlood and lymphatic system disorders18/42517/42724/428

Baseline characteristics

Age, Customized
Age, Customized(Participants)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
≥ 80 years878190258
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
Female sex195193184572
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
White4044104041218
Asian20152459
Black35210
Median Age
Median Age(years)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
Median75 (69 to 79)74 (69 to 78)74 (69 to 79)74 (69 to 78)
Region of Enrollment
Region of Enrollment(Participants)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
North America126106103335
Europe282309305896
Asia19152256
Median body-mass index (IQR)
Median body-mass index (IQR)(kg/m²)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
Median29.5 (26.0 to 33.6)30.0 (26.7 to 34.5)30.3 (27.0 to 34.4)29.9 (26.6 to 34.2)
Creatinine clearance ≤50 ml/min
Creatinine clearance ≤50 ml/min(Participants)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
Count of participants869088264
Pattern of atrial fibrillation
Pattern of atrial fibrillation(Participants)Abelacimab 90 mg (MAA868)Abelacimab 150 mg (MAA868)RivaroxabanTotal
First detected or paroxysmal224220225669
Persistent or long-standing persistent878497268
Permanent115120106341

13 further baseline measures are reported on the registry.

08

Study locations

92 sites
  • Anthos Investigative Site
    Huntsville, Alabama 35801, United States
  • Anthos Investigative Site
    Mobile, Alabama 36608, United States
  • Anthos Investigative Site
    Stamford, Connecticut 06905, United States
  • Anthos Investigative Site
    Clearwater, Florida 33756, United States
  • Anthos Investigative Site
    Daytona Beach, Florida 32114-2321, United States
  • Anthos Investigative Site
    Largo, Florida 33777, United States
  • Anthos Investigative Site
    Safety Harbor, Florida 34695, United States
  • Anthos Investigative Site
    Saint Augustine, Florida 32086, United States
  • Anthos Investigative Site
    Johns Creek, Georgia 30024, United States
  • Anthos Investigative Site
    Owensboro, Kentucky 42303, United States
  • Anthos Investigative Site
    Baltimore, Maryland 21229-5222, United States
  • Anthos Investigative Site
    Salisbury, Maryland 21804, United States
  • Anthos Investigative Site
    Framingham, Massachusetts 01701, United States
  • Anthos Investigative Site
    Haverhill, Massachusetts 01830, United States
  • Anthos Investigative Site
    Lansing, Michigan 48912, United States
  • Anthos Investigative Site
    Sewell, New Jersey 08080, United States
  • Anthos Investigative Site
    Poughkeepsie, New York 12601, United States
  • Anthos Investigative Site
    Southampton, New York 11968, United States
  • Anthos Investigative Site
    Lenoir, North Carolina 28645, United States
  • Anthos Investigative Site
    Fargo, North Dakota 58104, United States
  • Anthos Investigative Site
    Oklahoma City, Oklahoma 73135, United States
  • Anthos Investigative Site
    Camp Hill, Pennsylvania 17011, United States
  • Anthos Investigative Site
    Kingsport, Tennessee 37660, United States
  • Anthos Investigative Site
    Kingwood, Texas 77339, United States
  • Anthos Investigative Site
    Odessa, Texas 79761-5133, United States
  • Anthos Investigative Site
    Tomball, Texas 77375, United States
  • Anthos Investigative Site
    Falls Church, Virginia 22042, United States
  • Anthos Investigative Site
    Manassas, Virginia 20109, United States
  • Anthos Investigative Site
    Cambridge, Ontario N1R 7R1, Canada
  • Anthos Investigative Site
    Greater Sudbury, Ontario P3B 4H5, Canada
  • Anthos Investigative Site
    Oshawa, Ontario L1J2K1, Canada
  • Anthos Investigative Site
    Greenfield Park, Quebec J4V 2G8, Canada
  • Anthos Investigative Site
    Montreal, Quebec H1T 3Y7, Canada
  • Anthos Investigative Site
    Brandýs nad Labem, Central Bohemia 250 01, Czechia
  • Anthos Investigative Site
    Poděbrady, Central Bohemia 29001, Czechia
  • Anthos Investigative Site
    Příbram, Central Bohemia 261 01, Czechia
  • Anthos Investigative Site
    Slaný, Central Bohemia 274 01, Czechia
  • Anthos Investigative Site
    Mariánské Lázně, KA 353 01, Czechia
  • Anthos Investigative Site
    Trutnov, KR 541 01, Czechia
  • Anthos Investigative Site
    Liberec, LB 460 01, Czechia
  • Anthos Investigative Site
    Česká Lípa, LI 470 01, Czechia
  • Anthos Investigative Site
    Liberec, LI 460 01, Czechia
  • Anthos Investigative Site
    Pardubice, PA 530 02, Czechia
  • Anthos Investigative Site
    Prague, PR 10100, Czechia
  • Anthos Investigative Site
    Prague, PR 110 00, Czechia
  • Anthos Investigative Site
    Prague, PR 158 00, Czechia
  • Anthos Investigative Site
    Kroměříž, ZL 767 01, Czechia
  • Anthos Investigative Site
    Holešov, Zlín 769 01, Czechia
  • Anthos Investigative Site
    Orosháza, BE 5900, Hungary
  • Anthos Investigative Site
    Baja, BK 6500, Hungary
  • Anthos Investigative Site
    Budapest, BP 1036, Hungary
  • Anthos Investigative Site
    Budapest, BP 1122, Hungary
  • Anthos Investigative Site
    Budapest, BU 1033, Hungary
  • Anthos Investigative Site
    Budapest, BU 1134, Hungary
  • Anthos Investigative Site
    Székesfehérvár, FE 8000, Hungary
  • Anthos Investigative Site
    Debrecen, HB 4025, Hungary
  • Anthos Investigative Site
    Kaposvár, SO 7400, Hungary
  • Anthos Investigative Site (4002)
    Nyíregyháza, SZ 4400, Hungary
  • Anthos Investigative Site (4003)
    Nyíregyháza, SZ 4400, Hungary
  • Anthos Investigative Site
    Balatonfüred, VE 8230, Hungary
  • Anthos Investigative Site
    Balatonfüred, VM 8230, Hungary
  • Anthos Investigative Site
    Gdynia, GDY 81-423, Poland
  • Anthos Investigative Site
    Chrzanów, Lesser Poland Voivodeship 32-500, Poland
  • Anthos Investigative Site
    Krakow, Lesser Poland Voivodeship 31-202, Poland
  • Anthos Investigative Site
    Wroclaw, Lower Silesian Voivodeship 51-162, Poland
  • Anthos Investigative Site
    Żarów, Lower Silesian Voivodeship 58-130, Poland
  • Anthos Investigative Site
    Lublin, Lublin Voivodeship 20-001, Poland
  • Anthos Investigative Site
    Zamość, Lubusz Voivodeship 22-400, Poland
  • Anthos Investigative Site
    Płock, Masovian Voivodeship 09-402, Poland
  • Anthos Investigative Site
    Warsaw, Masovian Voivodeship 02-097, Poland
  • Anthos Investigative Site
    Warsaw, Masovian Voivodeship 04-628, Poland
  • Anthos Investigative Site
    Przemyśl, Podkarpackie Voivodeship 37-700, Poland
  • Anthos Investigative Site
    Gdynia, Pomeranian Voivodeship 81-157, Poland
  • Anthos Investigative Site
    Bielsko-Biala, Silesian Voivodeship 43-316, Poland
  • Anthos Investigative Site
    Dąbrowa Górnicza, Silesian Voivodeship 41-300, Poland
  • Anthos Investigative Site
    Ruda Śląska, Silesian Voivodeship 41-710, Poland
  • Anthos Investigative Site
    Tychy, Silesian Voivodeship 43-100, Poland
  • Anthos Investigative Site
    Elblag, Warmian-Masurian Voivodeship 82-300, Poland
  • Anthos Investigative Site
    Lodz, Łódź Voivodeship 92-213, Poland
  • Anthos Investigative Site
    Seogu, Busan 49201, South Korea
  • Anthos Investigative Site
    Seongnam-si, Gyeonggi-do 13496, South Korea
  • Anthos Investigative Site
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Anthos Investigative Site
    Seoul, Seoul 158-710, South Korea
  • Anthos Investigative Site
    Seoul, Seoul 3080, South Korea
  • Anthos Investigative Site
    Seoul, Seoul 3722, South Korea
  • Anthos Investigative Site
    Taipei, HSZ 30071, Taiwan
  • Anthos Investigative Site
    Hualien City, HUA 970, Taiwan
  • Anthos Investigative Site
    Yilan, ILA 26058, Taiwan
  • Anthos Investigative Site
    Kaohsiung City, KHH 807, Taiwan
  • Anthos Investigative Site
    Taipei, TPE 11217, Taiwan
  • Anthos Investigative Site
    Taipei, TPE 116, Taiwan
  • Anthos Investigative Site
    Tiachung, TXG 404, Taiwan
09

References and documents

Publications

  • Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, Goodrich EL, Chen SA, Goodman SG, Joung B, Kiss RG, Spinar J, Wojakowski W, Weitz JI, Murphy SA, Wiviott SD, Parkar S, Bloomfield D, Sabatine MS; AZALEA-TIMI 71 Investigators. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. N Engl J Med. 2025 Jan 23;392(4):361-371. doi: 10.1056/NEJMoa2406674. PubMed 39842011 ↗
  • Small AM, Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT. Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71. Blood. 2026 May 29:blood.2026033829. doi: 10.1182/blood.2026033829. Online ahead of print. PubMed 42213637 ↗
  • Al Said S, Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT. Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial. JAMA Cardiol. 2026 Mar 1;11(3):298-303. doi: 10.1001/jamacardio.2025.5418. PubMed 41637102 ↗
  • Al Said S, Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. Circulation. 2025 Aug 5;152(5):290-296. doi: 10.1161/CIRCULATIONAHA.125.074037. Epub 2025 Jun 23. PubMed 40546068 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Feb 2024, 36 months.

Results were first posted in Jul 2025, 1 year 5 months after primary completion. A results delay was requested in Feb 2025.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2021
First posted
Feb 16, 2021
StartActual
Feb 2, 2021
Primary completionActual
Feb 15, 2024
CompletionEst.
Dec 29, 2028
Results delay requested
Feb 14, 2025
Results first posted
Jul 30, 2025
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04755283
Lead sponsor
Anthos Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 16, 2021
Start date
Feb 2, 2021
Primary completion
Feb 15, 2024
Completion
Dec 29, 2028 (estimated)
Results posted
Jul 30, 2025
Last update
Nov 6, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abelacimab

Start the discussion